Literature DB >> 7284240

Oestrogen-receptor status and sites of metastasis in breast cancer.

F C Campbell, R W Blamey, C W Elston, R I Nicholson, K Griffiths, J L Haybittle.   

Abstract

The oestrogen receptor (RE) status of the primary tumour has been assessed in 466 of a consecutive series of 550 patients with primary operable breast cancer. All patients were followed up (without treatment) until the development of recurrence or metastases. Distant metastases have so far occurred in 124 patients and 82 have had symptomatic local or regional recurrence. A significant correlation exists between the RE status of the primary tumour and subsequent patterns of metastasis. Symptomatic metastases to regional lymph nodes are more common with RE- cancers. There is no significant difference in either time of onset or total incidence of distant metastases between patients with RE+ and RE- tumours. Distribution of distant metastases is influenced by RE status: RE+ tumours tend to recur in bone, RE- tumours show affinity for viscera.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7284240      PMCID: PMC2010785          DOI: 10.1038/bjc.1981.205

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Classification of patients with disseminated cancer of the breast.

Authors:  S J Cutler; J A Ardyce; S G Taylor
Journal:  Cancer       Date:  1969-11       Impact factor: 6.860

Review 2.  The management of advanced breast cancer.

Authors:  M Baum
Journal:  Br J Hosp Med       Date:  1980-01

3.  Fate of patients with recurrent carcinoma of the breast. Recurrence five or more years after initial treatment.

Authors:  A N Papaioannou; F J Tanz; H Volk
Journal:  Cancer       Date:  1967-03       Impact factor: 6.860

4.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.

Authors:  J S Meyer; B R Rao; S C Stevens; W L White
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

5.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  Estrogen receptor assay in primary breast cancer and early recurrence of the disease.

Authors:  P V Maynard; R W Blamey; C W Elston; J L Haybittle; K Griffiths
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

7.  Relationship of oestrogen-receptor status to survival in breast cancer.

Authors:  H M Bishop; R W Blamey; C W Elston; J L Haybittle; R I Nicholson; K Griffiths
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321

8.  The surgical implications of estrophile protein estimations in carcinoma of the breast.

Authors:  A J Walt; A Singhakowinta; S C Brooks; A Cortez
Journal:  Surgery       Date:  1976-10       Impact factor: 3.982

9.  Prognostic value of estrogen receptors in primary breast cancer.

Authors:  R Hähnel; T Woodings; A B Vivian
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

10.  Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.

Authors:  M M Roberts; R D Rubens; R J King; R A Hawkins; R R Millis; J L Hayward; A P Forrest
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

View more
  23 in total

1.  Luminal breast cancer metastasis is dependent on estrogen signaling.

Authors:  Vidya Ganapathy; Whitney Banach-Petrosky; Wen Xie; Aparna Kareddula; Hilde Nienhuis; Gregory Miles; Michael Reiss
Journal:  Clin Exp Metastasis       Date:  2012-03-17       Impact factor: 5.150

2.  Immunoblotting for breast carcinoma in infiltrated lymph nodes.

Authors:  A A Hakim; M Durkin
Journal:  Naturwissenschaften       Date:  1988-07

3.  Proteinase-like peptidase activities and oestrogen receptor levels in breast cancer tissue.

Authors:  A Vasishta; P R Baker; P E Preece; R A Wood; A Cuschieri
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Steroid hormone receptors and their clinical significance in cancer.

Authors:  R I Nicholson; R A McClelland; J M Gee
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

5.  Mechanisms in endocrine therapy of bone metastases.

Authors:  B A Stoll
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

6.  Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status.

Authors:  C Rose; H T Mouridsen; S M Thorpe; J Andersen; M Blichert-Toft; K W Andersen
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

7.  Cellular effects of tamoxifen in primary breast cancer.

Authors:  J F Robertson; I O Ellis; R I Nicholson; A Robins; J Bell; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1992-01       Impact factor: 4.872

8.  Metastatic pattern and response to endocrine therapy in human breast cancer.

Authors:  C Kamby; C Rose
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

9.  Identification of estrogen-responsive genes involved in breast cancer metastases to the bone.

Authors:  Jun Wang; Jennifer Jarrett; Chiang-Ching Huang; Robert L Satcher; Anait S Levenson
Journal:  Clin Exp Metastasis       Date:  2007-06-26       Impact factor: 5.150

10.  Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.

Authors:  A Valentin-Opran; G Eilon; S Saez; G R Mundy
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.